Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products (FDA Guidance for Industry)
Summary
The U.S. Food and Drug Administration (FDA) permits the use of a validated Container Closure Integrity Test (CCIT) in lieu of sterility testing within stability protocols for sterile products, provided the method is appropriately validated and justified.
This approach reflects FDA’s recognition that CCIT provides a direct, deterministic assessment of container closure integrity, while sterility testing is probabilistic and may fail to detect low-level breaches. By evaluating the physical barrier of the packaging, CCIT can identify potential failures before contamination occurs.
Importantly, sterility testing remains a compendial and regulatory requirement for initial batch release (per USP <71> and 21 CFR 211.167); CCIT substitution applies only to ongoing stability studies.
Official Source
These related links show posts on this site that reference this page. They do not necessarily mean that this guidance directly applies to every modality, product type, or quality attribute listed below.